DRAFT AGENDA

Alliance for Clinical Trials in Oncology
May 10, 2018
Lowes Chicago O'Hare Hotel
Rosemont, IL
1:30-4:30
Room: TBD

Respiratory Committee

Chair: Tom Stinchcombe, M.D.
Vice-Chairs: Dennis Wigle (Surgery)
Steven Schild (Radiation Oncology)
Stephen Graziano (Translational medicine)

1. Committee overview, and protocol accrual – Chair and Xiaofei Wang

2. Recently completed studies

1. Squamous predictive marker: Raphael Bueno

3. Intergroup studies

1. NRG LU002: Pranshu Mohindra
2. EA5163 (INSIGNIA): Erin Bertino
3. EA5152: Muhammad Furqan
4. Lung MAP-pembrolizumab/ramucirumab Konstantin Dragnev
5. Lung Master Protocol– Lyudmila Bazhenova


5. Stage IV Non-Small Cell Lung Cancer

1. A221504 - Peripheral Opioid Receptor Antagonist in NSCLC – Pankaj Gupta,
Lyudmila Bazhenova
2. **AFT-42**: Nivolumab for patients with compromised organ function – Becca Heist, Phil Stella

3. **Brain metastases in EGFR/ALK positive patients**: SRS vs targeted therapy – Luda Bazhenova

4. **Brain metastases in mutation negative patients**: chemotherapy + pembrolizumab – Mark Awad

6. **Stage III Non-Small Cell Lung Cancer**
   1. **AFT-16**: Induction PDL-1 inhibition – Helen Ross, Jim Urbanic
   2. **AFT-46**: Chemo-immunotherapy for operable stage III NSCLC – Linda Martin

7. **Early Stage Non-Small Cell Lung Cancer and Surgical Studies** – Dennis Wigle
   1. **A151216/081105- ALCHEMIST- Screening trial and analysis update** – Geoffrey Oxnard, Ramaswamy Govindan, Dennis Wigle, Sumithra Mandrekar
   2. **Adjuvant chemotherapy alone or in combination with pembrolizumab** – Jacob Sands

8. **Small Cell Lung Cancer**
   1. **CALGB 30610**: Limited Stage Intergroup Trial – Jeffrey Bogart and Greg Masters
   2. **NRG 003**: ChemoRT +/- atezolizumab – Helen Ross
   3. **Concept for discussion**: SRS vs WBRT – Steve Schild
   4. **Concept for discussion**: Lurbinectedin maintenance trial – Jeff Petty
   5. **Concept for discussion**: Early stage SCLC – Steve Chun

9. **Ongoing projects from other committees**